ArticleTurkish journal of medical sciences2024
Investigating the biomarker potential and molecular targets of TIGD1 in lung cancer using bioinformatics.
Article in Turkish journal of medical sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Histological Evaluation ofBiomedicines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/aim: Lung cancer, a predominant contributor to cancer mortality, is characterized by diverse etiological factors, including tobacco smoking and genetic susceptibilities. Despite advancements, particularly in nonsmall-cell lung cancer (NSCLC), therapeutic options for lung squamous cell carcinoma (LUSC) are limited. Transposable elements (TEs) and their regulatory proteins, such as tigger transposable element derived (TIGD) family proteins, have been implicated in cancer development. TIGD1, upregulated in various cancers, including LUSC, lacks a defined function. The aim of our study was to elucidate the biological functions, associated pathways, and interacting proteins of TIGD1. Materials and methods: The GSE229260 microarray dataset was investigated using the GEO2R tool to identify the differentially expressed genes (DEGs) in TIGD1 silenced in A549 lung cancer cells in contrast to controls. Enrichment analyses and protein-protein interaction (PPI) network construction were performed to uncover key pathways using KEGG and STRING analyses. Hub genes were determined through the intersection of DEGs with lung cancer-related genes via Cytoscape software and the cytoHubba plug-in, and their functions were analyzed. Immune and stromal scores of hub genes were also evaluated using the ESTIMATE algorithm. Results: Analyzing microarray data from TIGD1-silenced A549 NSCLC cells, a total of 13 upregulated DEGs and 1 downregulated DEGs were identified. The TIGD1-associated DEGs revealed significant involvement in crucial molecular pathways, including the PI3K/AKT, FOXO, and p53 signaling pathways. The hub genes AKT1, BRAF, SRC, GAPDH, CCND1, CDKN2A, CTNNB1, KRAS, MYC, and TP53 emerged as central regulators of cell proliferation, apoptosis, and protein metabolism. The hub genes exhibited negative correlations with immune and stromal components in the tumor microenvironment, suggesting their potential as biomarkers for lung cancer therapy. Conclusion: This study elucidates the potential functions of TIGD1 in lung cancer and identifies promising biomarker candidates associated with TIGD1 gene expression, presenting potential therapeutic targets for lung cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.